A couple suing Johnson & Johnson and its longtime talc supplier Imerys Talc America received a mixed-bag ruling Wednesday after a Pennsylvania federal court shot down Imerys’ bid to dismiss itself on jurisdictional grounds, but refused to send the suit back to state court.
Medical device company Neurvana Medical LLC filed a lawsuit in Delaware Chancery Court on Thursday claiming competitor Balt USA LLC and its president are trying to sabotage and destroy Neurvana after the president was ousted from its board for alleged hostile behavior.
With the partial government shutdown in its fourth week, Spectrum Pharmaceuticals Inc. and Acrotech Biopharma LLC incorporated protection against the delay of required regulatory approvals into Thursday's announced contract for a drug portfolio sale, a move other dealmakers will likely follow even after the shutdown ends.
New York City has added members of the family that controls OxyCodone developer Purdue Pharma LP and four major pharmaceutical retailers to its suit alleging drugmakers and distributors misrepresented the safety of their opioids to drive sales.
Lens.com Inc. lost a bid to kill or move a trademark case to its home state of Nevada on Thursday, after a New York federal judge decided contact lens maker Alcon Laboratories Inc. had properly brought the suit in the Brooklyn-based court.
Citing a commitment to listen to the will of the people, Florida Gov. Ron DeSantis said Thursday that the State Legislature should remove a smoking ban on medical marijuana or he will drop the state's defense of the policy in a pending lawsuit.
Biotechnology company Revance Therapeutics said on Thursday that it has priced a $100 million follow-on offering by way of a preapproved U.S. Securities and Exchange Commission filing that will allow the company to raise funds despite the uncertainty surrounding the market due to the government shutdown.
Bristol-Myers Squibb made headlines this month with its mammoth takeover of Celgene, but the vast majority of dealmaking in the life sciences space this year will be smaller transactions aimed at acquiring promising drug therapies and technologies, according to Asher Rubin, global head of Hogan Lovells LLP’s life sciences industry group.
A class of diabetes patients alleging the three top insulin manufacturers colluded to drive up medicine prices for the uninsured and underinsured told a New Jersey federal judge Thursday they have standing to file a racketeering claim because they're the only ones in the supply chain injured by the practice.
The Delaware Supreme Court on Thursday upheld a Chancery Court dismissal of global health care and biosecurity company BioVeris Corp.'s roughly $3 million breach of contract dispute with a former partner, rejecting the company’s argument the lower court misapplied statute of limitations standards.
Seafood company Nippon Suisan Kaisha Ltd. won its challenge in post-grant review to a patent on a process for purifying fish oil on Wednesday, with the Patent Trial and Board finding many claims in the patent were too vague.
A former Ballard Spahr LLP intellectual property partner has joined the ranks of Stevens & Lee PC outside Philadelphia to take on a new role as co-chair of the firm's technology, telecommunications and life sciences practice.
Alzheimer’s-focused biotechnology firm Alzheon Inc. said Wednesday it is no longer looking to go public, marking the second time the Framingham, Massachusetts-based company has canceled plans for an initial public offering in the past year.
Weil Gotshal & Manges LLP has amassed numerous wins in federal court in the past year — including a nearly $27 million jury win for Illumina Inc. in a patent suit — landing its life sciences team among Law360's Practice Groups of the Year.
Members of a New Jersey state appellate panel offered divergent views Wednesday on whether a lawyer had presented enough evidence to back up his class claims that homeopathic medicine from King Bio Inc. is falsely marketed as a treatment for the flu, a product he referred to as “a bottle of broken promises.”
Pfizer Inc. can’t enforce an arbitration clause that it never made its employees explicitly agree to, a New Jersey appeals court said Wednesday, clearing a former corporate flight attendant to sue for religious discrimination.
A pathologist fielded questions in a California courtroom Wednesday from jurors considering whether Johnson & Johnson baby powder contained asbestos that caused a dying woman’s cancer, explaining that the asbestos amounts found in the woman’s lung tissue and lymph nodes were too high to have come from ambient air.
The Missouri Supreme Court has granted Johnson & Johnson's last-minute bid to pause a trial on claims that asbestos in the pharmaceutical giant's talcum powder products gave 13 women ovarian cancer, issuing a stay days before jury selection was scheduled to begin in St. Louis.
Outcome Health named its first chief compliance officer Wednesday, tasking him with overhauling an existing compliance program as the Chicago startup tries to move past investor allegations that it overcharged drugmakers for the electronic advertisements it runs alongside medical information in doctors’ offices.
Pet medicine distributor PetIQ has urged a California federal court to toss an amended suit brought by two rivals seeking to block its purchase of a veterinary clinic chain, saying the antitrust suit lacks the flesh it was asked to add to the first version.
The lack of minority partners comes at a high cost to firms, say attorneys at Lightfoot Franklin & White LLC, as they suggest several practical ways to tackle this problem.
The Federal Circuit's ruling last week in Amerigen v. UCB provides an informative data point regarding standing for inter partes review appeals in the Hatch-Waxman context, as well as considerations for brand companies facing obviousness challenges to patents claiming prodrug compounds, say attorneys with King & Spalding LLP.
The patent landscape for cannabis is conforming roughly to that of traditional biopharma in terms of the rejections being raised and how they are being overcome, say Pauline Pelletier and Deborah Sterling of Sterne Kessler Goldstein & Fox PLLC.
In the final installment of their four-part series, attorneys with Skadden Arps Slate Meagher & Flom LLP focus on corporate governance best practices such as disclosures related to board evaluations and virtual shareholder meetings; the status of Dodd-Frank and other U.S. Securities and Exchange Commission rule-making matters; and considerations in assessing social media policies.
In the third installment of their four-part series, attorneys with Skadden Arps Slate Meagher & Flom LLP consider corporate governance best practices including environmental, social and governance reporting, updates to director and officer questionnaires, board diversity and related disclosures, and shareholder proposals.
The Office of Inspector General at the U.S. Department of Health and Human Services entered into only 37 new corporate integrity agreements last year — the lowest number since 2012 — but it was an important year on the policy front, say attorneys with Skadden Arps Slate Meagher & Flom LLP.
English courts have been active in the past year, grappling with patent topics like plausibility and equivalents, and 2019 promises to be another exciting year as English patent lawyers await developments on obviousness, insufficiency and employee inventor compensation, says Jin Ooi of Kirkland & Ellis LLP.
Alternative dispute resolution providers have made great strides toward diversity, but recent statistics show there is still work to be done. There are certain steps ADR providers can take to actively recruit more women and minority candidates to serve as arbitrators and mediators, says James Jenkins of the American Arbitration Association.
Alternative fee agreements can help align law firm and client interests, increase efficiency and eliminate corporate extortion, among other benefits. They are the best thing to happen to the practice of law in decades, says Kelly Eisenlohr-Moul at Dinsmore & Shohl LLP.
In New Haven v. Purdue, a Connecticut state judge ruled last week that opioid manufacturers are not liable for cities' emergency and social services costs. This decision protects liability insurance from being transformed into a funding mechanism for social problems that it was not designed to cover, say Patrick Bedell and Kevin Harris of BatesCarey LLP.